However, because transient silencing of gene expression rarely eliminates its target completely, we next compared genetically STAT3-deficient PC3 prostate cancer cells and the STAT3-proficient MDA-MB-231 breast cancer cells. This evidence concerns the gene STAT3 and prostate carcinoma.